CoChat
Sign Up
Cited by 150

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The developing story of Sprouty and cancer

Masoumi-Moghaddam, Samar, Amini, Afshin, Morris, David Lawson·2014·Cancer and Metastasis Reviews
DOI 10.1007/s10555-014-9497-1PMC PMC4113681
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10555-014-9497-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GGAs regulate TGN-endosome trafficking of many cargo molecules with ACLL motifs including sortilin, mannose-6-phosphate receptors, B-secretase, stabilin-1, chloride channel 7, consortin and others.

    “In this manner, GGAs have been shown to regulate the TGN-endosome trafficking of many cargo molecules with ACLL motifs including sortilin32, manose-6-phosphate receptors33, B-secretase34, stabilin-134, chloride channel 734, consortin35 and others.”

    From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [34]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 171

  1. Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y., & Krasnow, M. A. (1998). Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell, 92(2), 253–263. · DOI
  2. Kramer, S., Okabe, M., Hacohen, N., Krasnow, M. A., & Hiromi, Y. (1999). Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Development, 126(11), 2515–2525. · DOI
  3. de Maximy, A. A., Nakatake, Y., Moncada, S., Itoh, N., Thiery, J. P., & Bellusci, S. (1999). Cloning and expression pattern of a mouse homologue of drosophila sprouty in the mouse embryo. [Research Support, Non-U.S. Gov't]. Mechanisms of Development, 81(1–2), 213–216. · DOI
  4. Leeksma, O. C., Van Achterberg, T. A., Tsumura, Y., Toshima, J., Eldering, E., Kroes, W. G., et al. (2002). Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. European Journal of Biochemistry, 269(10), 2546–2556. · DOI
  5. Gross, I., Bassit, B., Benezra, M., & Licht, J. D. (2001). Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. Journal of Biological Chemistry, 276(49), 46460–46468. doi: 10.1074/jbc.M108234200 . · DOI
  6. Impagnatiello, M. A., Weitzer, S., Gannon, G., Compagni, A., Cotten, M., & Christofori, G. (2001). Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. Journal of Cell Biology, 152(5), 1087–1098. · DOI
  7. Wong, E. S., Fong, C. W., Lim, J., Yusoff, P., Low, B. C., Langdon, W. Y., et al. (2002). Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO Journal, 21(18), 4796–4808. · DOI
  8. Gross, I., Armant, O., Benosman, S., de Aguilar, J. L., Freund, J. N., Kedinger, M., et al. (2007). Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation, 14(10), 1802–1812. doi: 10.1038/sj.cdd.4402188 . · DOI
  9. Ishida, M., Ichihara, M., Mii, S., Jijiwa, M., Asai, N., Enomoto, A., et al. (2007). Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase. Cancer Science, 98(6), 815–821. doi: 10.1111/j.1349-7006.2007.00457.x . · DOI
  10. Minowada, G., Jarvis, L. A., Chi, C. L., Neubuser, A., Sun, X., Hacohen, N., et al. (1999). Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Development, 126(20), 4465–4475. · DOI
  11. Ding, W., Bellusci, S., Shi, W., & Warburton, D. (2004). Genomic structure and promoter characterization of the human Sprouty4 gene, a novel regulator of lung morphogenesis. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. American Journal of Physiology - Lung Cellular and Molecular Physiology, 287(1), L52–L59. doi: 10.1152/ajplung.00430.2003 . · DOI
  12. Tefft, J. D., Lee, M., Smith, S., Leinwand, M., Zhao, J., Bringas, P., Jr., et al. (1999). Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. [Research Support, U.S. Gov't, P.H.S.]. Current Biology, 9(4), 219–222. · DOI
  13. Katoh, Y., & Katoh, M. (2006). FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. International Journal of Molecular Medicine, 17(3), 529–532.
  14. Cabrita, M. A., & Christofori, G. (2008). Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis, 11(1), 53–62. doi: 10.1007/s10456-008-9089-1 . · DOI
  15. Horowitz, A., & Simons, M. (2008). Branching morphogenesis. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. Circulation Research, 103(8), 784–795. doi: 10.1161/CIRCRESAHA.108.181818 . · DOI
  16. Warburton, D. (2008). Developmental biology: Order in the lung. Nature, 453(7196), 733–735. doi: 10.1038/453733a . · DOI
  17. Furthauer, M., Reifers, F., Brand, M., Thisse, B., & Thisse, C. (2001). Sprouty4 acts in vivo as a feedback-induced antagonist of FGF signaling in zebrafish. [Research Support, Non-U.S. Gov't]. Development, 128(12), 2175–2186. · DOI
  18. Zhang, S., Lin, Y., Itaranta, P., Yagi, A., & Vainio, S. (2001). Expression of Sprouty genes 1, 2 and 4 during mouse organogenesis. Mechanisms of Development, 109(2), 367–370. · DOI
  19. Gross, I., Morrison, D. J., Hyink, D. P., Georgas, K., English, M. A., Mericskay, M., et al. (2003). The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development. Journal of Biological Chemistry, 278(42), 41420–41430. doi: 10.1074/jbc.M306425200 . · DOI
  20. Chi, L., Zhang, S., Lin, Y., Prunskaite-Hyyrylainen, R., Vuolteenaho, R., Itaranta, P., et al. (2004). Sprouty proteins regulate ureteric branching by coordinating reciprocal epithelial Wnt11, mesenchymal Gdnf and stromal Fgf7 signalling during kidney development. Development, 131(14), 3345–3356. doi: 10.1242/dev.01200 . · DOI
  21. Lo, T. L., Yusoff, P., Fong, C. W., Guo, K., McCaw, B. J., Phillips, W. A., et al. (2004). The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Research, 64(17), 6127–6136. doi: 10.1158/0008-5472.CAN-04-1207 . · DOI
  22. Anteby, E. Y., Natanson-Yaron, S., Greenfield, C., Goldman-Wohl, D., Haimov-Kochman, R., Holzer, H., et al. (2005). Human placental Hofbauer cells express sprouty proteins: a possible modulating mechanism of villous branching. Placenta, 26(6), 476–483. doi: 10.1016/j.placenta.2004.08.008 . · DOI
  23. Haimov-Kochman, R., Ravhon, A., Prus, D., Greenfield, C., Finci-Yeheskel, Z., Goldman-Wohl, D. S., et al. (2005). Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. Molecular Human Reproduction, 11(8), 537–542. doi: 10.1093/molehr/gah203 . · DOI
  24. Lin, W., Jing, N., Basson, M. A., Dierich, A., Licht, J., & Ang, S. L. (2005). Synergistic activity of Sef and Sprouty proteins in regulating the expression of Gbx2 in the mid-hindbrain region. Genesis, 41(3), 110–115. doi: 10.1002/gene.20103 . · DOI
  25. Shim, K., Minowada, G., Coling, D. E., & Martin, G. R. (2005). Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Developmental Cell, 8(4), 553–564. doi: 10.1016/j.devcel.2005.02.009 . · DOI
  26. Basson, M. A., Watson-Johnson, J., Shakya, R., Akbulut, S., Hyink, D., Costantini, F. D., et al. (2006). Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Developmental Biology, 299(2), 466–477. doi: 10.1016/j.ydbio.2006.08.051 . · DOI
  27. Boros, J., Newitt, P., Wang, Q., McAvoy, J. W., & Lovicu, F. J. (2006). Sef and Sprouty expression in the developing ocular lens: Implications for regulating lens cell proliferation and differentiation. Seminars in Cell and Developmental Biology, 17(6), 741–752. doi: 10.1016/j.semcdb.2006.10.007 . · DOI
  28. Chi, L., Itaranta, P., Zhang, S., & Vainio, S. (2006). Sprouty2 is involved in male sex organogenesis by controlling fibroblast growth factor 9-induced mesonephric cell migration to the developing testis. Endocrinology, 147(8), 3777–3788. doi: 10.1210/en.2006-0299 . · DOI
  29. Natanson-Yaron, S., Anteby, E. Y., Greenfield, C., Goldman-Wohl, D., Hamani, Y., Hochner-Celnikier, D., et al. (2007). FGF 10 and Sprouty 2 modulate trophoblast invasion and branching morphogenesis. Molecular Human Reproduction, 13(7), 511–519. doi: 10.1093/molehr/gam034 . · DOI
  30. Price, K. L., Long, D. A., Jina, N., Liapis, H., Hubank, M., Woolf, A. S., et al. (2007). Microarray interrogation of human metanephric mesenchymal cells highlights potentially important molecules in vivo. Physiological Genomics, 28(2), 193–202. doi: 10.1152/physiolgenomics.00147.2006 . · DOI
  31. Laziz, I., Armand, A. S., Pariset, C., Lecolle, S., Della Gaspera, B., Charbonnier, F., et al. (2007). Sprouty gene expression is regulated by nerve and FGF6 during regeneration of mouse muscles. Growth Factors, 25(3), 151–159. doi: 10.1080/08977190701723166 . · DOI
  32. Hamel, M., Dufort, I., Robert, C., Gravel, C., Leveille, M. C., Leader, A., et al. (2008). Identification of differentially expressed markers in human follicular cells associated with competent oocytes. Human Reproduction, 23(5), 1118–1127. doi: 10.1093/humrep/den048 . · DOI
  33. Klein, O. D., Lyons, D. B., Balooch, G., Marshall, G. W., Basson, M. A., Peterka, M., et al. (2008). An FGF signaling loop sustains the generation of differentiated progeny from stem cells in mouse incisors. Development, 135(2), 377–385. doi: 10.1242/dev.015081 . · DOI
  34. Jaggi, F., Cabrita, M. A., Perl, A. K., & Christofori, G. (2008). Modulation of endocrine pancreas development but not beta-cell carcinogenesis by Sprouty4. Molecular Cancer Research, 6(3), 468–482. doi: 10.1158/1541-7786.mcr-07-0255 . · DOI
  35. Wang, Y., Janicki, P., Koster, I., Berger, C. D., Wenzl, C., Grosshans, J., et al. (2008). Xenopus paraxial protocadherin regulates morphogenesis by antagonizing Sprouty. Genes and Development, 22(7), 878–883. doi: 10.1101/gad.452908 . · DOI
  36. Pan, Y., Carbe, C., Powers, A., Feng, G. S., & Zhang, X. (2010). Sprouty2-modulated Kras signaling rescues Shp2 deficiency during lens and lacrimal gland development. Development, 137(7), 1085–1093. doi: 10.1242/dev.042820 . · DOI
  37. Purcell, P., Jheon, A., Vivero, M. P., Rahimi, H., Joo, A., & Klein, O. D. (2012). Spry1 and Spry2 are essential for development of the temporomandibular joint. Journal of Dental Research. doi: 10.1177/0022034512438401 . · DOI
  38. Sieglitz, F., Matzat, T., Yuva-Adyemir, Y., Neuert, H., Altenhein, B., & Klambt, C. (2013). Antagonistic feedback loops involving rau and sprouty in the Drosophila eye control neuronal and glial differentiation. Science Signaling, 6(300), ra96. doi: 10.1126/scisignal.2004651 . · DOI
  39. Kuracha, M. R., Siefker, E., Licht, J. D., & Govindarajan, V. (2013). Spry1 and Spry2 are necessary for eyelid closure. Developmental Biology, 383(2), 227–238. doi: 10.1016/j.ydbio.2013.09.014 . · DOI
  40. Velasco, A., Pallares, J., Santacana, M., Gatius, S., Fernandez, M., Domingo, M., et al. (2011). Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. Human Pathology, 42(2), 185–193. doi: 10.1016/j.humpath.2010.08.001 . · DOI
  41. Sigurdsson, V., Ingthorsson, S., Hilmarsdottir, B., Gustafsdottir, S. M., Franzdottir, S. R., Arason, A. J., et al. (2013). Expression and functional role of sprouty-2 in breast morphogenesis. PLoS One, 8(4), e60798. doi: 10.1371/journal.pone.0060798 . · DOI
  42. Ching, S. T., Cunha, G. R., Baskin, L. S., Basson, M. A., & Klein, O. D. (2014). Coordinated activity of Spry1 and Spry2 is required for normal development of the external genitalia. Developmental Biology, 386(1), 1–11. doi: 10.1016/j.ydbio.2013.12.014 . · DOI
  43. Lee, S. H., Schloss, D. J., Jarvis, L., Krasnow, M. A., & Swain, J. L. (2001). Inhibition of angiogenesis by a mouse sprouty protein. Journal of Biological Chemistry, 276(6), 4128–4133. doi: 10.1074/jbc.M006922200 . · DOI
  44. Huebert, R. C., Li, Q., Adhikari, N., Charles, N. J., Han, X., Ezzat, M. K., et al. (2004). Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart. Physiological Genomics, 18(3), 284–289. doi: 10.1152/physiolgenomics.00098.2004 . · DOI
  45. Poppleton, H. M., Edwin, F., Jaggar, L., Ray, R., Johnson, L. R., & Patel, T. B. (2004). Sprouty regulates cell migration by inhibiting the activation of Rac1 GTPase. Biochemical and Biophysical Research Communications, 323(1), 98–103. doi: 10.1016/j.bbrc.2004.08.070 . · DOI
  46. Zhang, C., Chaturvedi, D., Jaggar, L., Magnuson, D., Lee, J. M., & Patel, T. B. (2005). Regulation of vascular smooth muscle cell proliferation and migration by human sprouty 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(3), 533–538. doi: 10.1161/01.ATV.0000155461.50450.5a . · DOI
  47. de Alvaro, C., Martinez, N., Rojas, J. M., & Lorenzo, M. (2005). Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2. Molecular Biology of the Cell, 16(9), 4454–4461. doi: 10.1091/mbc.E05-05-0419 . · DOI
  48. Tsumura, Y., Toshima, J., Leeksma, O. C., Ohashi, K., & Mizuno, K. (2005). Sprouty-4 negatively regulates cell spreading by inhibiting the kinase activity of testicular protein kinase. Biochemical Journal, 387(Pt 3), 627–637. doi: 10.1042/BJ20041181 . · DOI
  49. Fong, C. W., Chua, M. S., McKie, A. B., Ling, S. H., Mason, V., Li, R., et al. (2006). Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Research, 66(4), 2048–2058. doi: 10.1158/0008-5472.CAN-05-1072 . · DOI
  50. Wang, J., Thompson, B., Ren, C., Ittmann, M., & Kwabi-Addo, B. (2006). Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate, 66(6), 613–624. doi: 10.1002/pros.20353 . · DOI
  51. Sutterluty, H., Mayer, C. E., Setinek, U., Attems, J., Ovtcharov, S., Mikula, M., et al. (2007). Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Molecular Cancer Research, 5(5), 509–520. doi: 10.1158/1541-7786.MCR-06-0273 . · DOI
  52. Ding, W., Shi, W., Bellusci, S., Groffen, J., Heisterkamp, N., Minoo, P., et al. (2007). Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells. Journal of Cellular Physiology, 212(3), 796–806. doi: 10.1002/jcp.21078 . · DOI
  53. Ding, W., & Warburton, D. (2008). Down-regulation of Sprouty2 via p38 MAPK plays a key role in the induction of cellular apoptosis by tumor necrosis factor-alpha. Biochemical and Biophysical Research Communications, 375(3), 460–464. doi: 10.1016/j.bbrc.2008.08.037 . · DOI
  54. Lito, P., Mets, B. D., Appledorn, D. M., Maher, V. M., & McCormick, J. J. (2009). Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. Journal of Biological Chemistry, 284(2), 848–854. doi: 10.1074/jbc.M808045200 . · DOI
  55. Tennis, M. A., Van Scoyk, M. M., Freeman, S. V., Vandervest, K. M., Nemenoff, R. A., & Winn, R. A. (2010). Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Molecular Cancer Research, 8(6), 833–843. doi: 10.1158/1541-7786.mcr-09-0400 . · DOI
  56. Jung, J. E., Moon, S. H., Kim, D. K., Choi, C., Song, J., & Park, K. S. (2012). Sprouty1 regulates neural and endothelial differentiation of mouse embryonic stem cells. Stem Cells and Development, 21(4), 554–561. doi: 10.1089/scd.2011.0110 . · DOI
  57. Felfly, H., & Klein, O. D. (2013). Sprouty genes regulate proliferation and survival of human embryonic stem cells. Science Reports, 3, 2277. doi: 10.1038/srep02277 . · DOI
  58. Mekkawy, A. H., & Morris, D. L. (2013). Human Sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion. ISRN Biochem, 2013, 7. doi: 10.1155/2013/598251 . · DOI
  59. Sasaki, A., Taketomi, T., Wakioka, T., Kato, R., & Yoshimura, A. (2001). Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor—but not epidermal growth factor-induced ERK activation. Journal of Biological Chemistry, 276(39), 36804–36808. doi: 10.1074/jbc.C100386200 . · DOI
  60. Yigzaw, Y., Cartin, L., Pierre, S., Scholich, K., & Patel, T. B. (2001). The C terminus of sprouty is important for modulation of cellular migration and proliferation. Journal of Biological Chemistry, 276(25), 22742–22747. doi: 10.1074/jbc.M100123200 . · DOI
  61. Yigzaw, Y., Poppleton, H. M., Sreejayan, N., Hassid, A., & Patel, T. B. (2003). Protein-tyrosine phosphatase-1B (PTP1B) mediates the anti-migratory actions of Sprouty. Journal of Biological Chemistry, 278(1), 284–288. doi: 10.1074/jbc.M210359200 . · DOI
  62. Lee, C. C., Putnam, A. J., Miranti, C. K., Gustafson, M., Wang, L. M., Vande Woude, G. F., et al. (2004). Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene, 23(30), 5193–5202. doi: 10.1038/sj.onc.1207646 . · DOI
  63. Edwin, F., Singh, R., Endersby, R., Baker, S. J., & Patel, T. B. (2006). The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. Journal of Biological Chemistry, 281(8), 4816–4822. doi: 10.1074/jbc.M508300200 . · DOI
  64. Edwin, F., & Patel, T. B. (2008). A novel role of Sprouty 2 in regulating cellular apoptosis. Journal of Biological Chemistry, 283(6), 3181–3190. doi: 10.1074/jbc.M706567200 . · DOI
  65. Lee, S. A., Ho, C., Roy, R., Kosinski, C., Patil, M. A., Tward, A. D., et al. (2008). Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology, 47(4), 1200–1210. doi: 10.1002/hep.22169 . · DOI
  66. Frank, M. J., Dawson, D. W., Bensinger, S. J., Hong, J. S., Knosp, W. M., Xu, L., et al. (2009). Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood, 113(11), 2478–2487. doi: 10.1182/blood-2008-05-156943 . · DOI
  67. Holgren, C., Dougherty, U., Edwin, F., Cerasi, D., Taylor, I., Fichera, A., et al. (2010). Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Oncogene, 29(38), 5241–5253. doi: 10.1038/onc.2010.264 . · DOI
  68. Barbachano, A., Ordonez-Moran, P., Garcia, J. M., Sanchez, A., Pereira, F., Larriba, M. J., et al. (2010). SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene, 29(34), 4800–4813. doi: 10.1038/onc.2010.225 . · DOI
  69. Schaaf, G., Hamdi, M., Zwijnenburg, D., Lakeman, A., Geerts, D., Versteeg, R., et al. (2010). Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Research, 70(2), 762–771. doi: 10.1158/0008-5472.can-09-2532 . · DOI
  70. Wang, C., Delogu, S., Ho, C., Lee, S. A., Gui, B., Jiang, L., et al. (2012). Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. Journal of Hepatology, 57(3), 577–583. doi: 10.1016/j.jhep.2012.04.026 . · DOI
  71. Alsina, F. C., Irala, D., Fontanet, P. A., Hita, F. J., Ledda, F., & Paratcha, G. (2012). Sprouty4 is an endogenous negative modulator of TrkA signaling and neuronal differentiation induced by NGF. PLoS One, 7(2), e32087. doi: 10.1371/journal.pone.0032087 . · DOI
  72. Schlessinger, J. (2004). Common and distinct elements in cellular signaling via EGF and FGF receptors. Science, 306(5701), 1506–1507. doi: 10.1126/science.1105396 . · DOI
  73. Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80(2), 179–185. · DOI · Paper page
  74. Kim, H. J., & Bar-Sagi, D. (2004). Modulation of signalling by Sprouty: a developing story. Nature Reviews Molecular Cell Biology, 5(6), 441–450. doi: 10.1038/nrm1400 . · DOI
  75. Sasaki, A., Taketomi, T., Kato, R., Saeki, K., Nonami, A., Sasaki, M., et al. (2003). Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nature Cell Biology, 5(5), 427–432. doi: 10.1038/ncb978 . · DOI
  76. Kao, S., Jaiswal, R. K., Kolch, W., & Landreth, G. E. (2001). Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. Journal of Biological Chemistry, 276(21), 18169–18177. doi: 10.1074/jbc.M008870200 . · DOI
  77. Ozaki, K., Kadomoto, R., Asato, K., Tanimura, S., Itoh, N., & Kohno, M. (2001). ERK pathway positively regulates the expression of Sprouty genes. [Research Support, Non-U.S. Gov't]. Biochemical and Biophysical Research Communications, 285(5), 1084–1088. doi: 10.1006/bbrc.2001.5295 . · DOI
  78. Kral, R. M., Mayer, C. E., Vanas, V., Gsur, A., & Sutterluty-Fall, H. (2013). In non-small cell lung cancer mitogenic signaling leaves Sprouty1 protein levels unaffected. Cell Biochemistry and Function. doi: 10.1002/cbf.2976 . · DOI
  79. Hausott, B., Vallant, N., Auer, M., Yang, L., Dai, F., Brand-Saberi, B., et al. (2009). Sprouty2 down-regulation promotes axon growth by adult sensory neurons. Molecular and Cellular Neuroscience, 42(4), 328–340. doi: 10.1016/j.mcn.2009.08.005 . · DOI
  80. Shea, K. L., Xiang, W., LaPorta, V. S., Licht, J. D., Keller, C., Basson, M. A., et al. (2010). Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration. Cell Stem Cell, 6(2), 117–129. doi: 10.1016/j.stem.2009.12.015 . · DOI · Paper page
  81. Choi, H., Cho, S. Y., Schwartz, R. H., & Choi, K. (2006). Dual effects of Sprouty1 on TCR signaling depending on the differentiation state of the T cell. Journal of Immunology, 176(10), 6034–6045. · DOI
  82. Jiang, Z., & Price, C. A. (2012). Differential actions of fibroblast growth factors on intracellular pathways and target gene expression in bovine ovarian granulosa cells. Reproduction, 144(5), 625–632. doi: 10.1530/rep-12-0199 . · DOI
  83. Jiang, Z., Guerrero-Netro, H. M., Juengel, J. L., & Price, C. A. (2013). Divergence of intracellular signaling pathways and early response genes of two closely related fibroblast growth factors, FGF8 and FGF18, in bovine ovarian granulosa cells. Molecular and Cellular Endocrinology, 375(1–2), 97–105. doi: 10.1016/j.mce.2013.05.017 . · DOI
  84. Ding, W., Bellusci, S., Shi, W., & Warburton, D. (2003). Functional analysis of the human Sprouty2 gene promoter. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Gene, 322, 175–185. · DOI
  85. Sabatel, C., Cornet, A. M., Tabruyn, S. P., Malvaux, L., Castermans, K., Martial, J. A., et al. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9, 231. doi: 10.1186/1476-4598-9-231 . · DOI
  86. Hall, A. B., Jura, N., DaSilva, J., Jang, Y. J., Gong, D., & Bar-Sagi, D. (2003). hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Current Biology, 13(4), 308–314. · DOI
  87. Rubin, C., Litvak, V., Medvedovsky, H., Zwang, Y., Lev, S., & Yarden, Y. (2003). Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Current Biology, 13(4), 297–307. · DOI
  88. Mason, J. M., Morrison, D. J., Bassit, B., Dimri, M., Band, H., Licht, J. D., et al. (2004). Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Molecular Biology of the Cell, 15(5), 2176–2188. doi: 10.1091/mbc.E03-07-0503 . · DOI
  89. Mason, J. M., Morrison, D. J., Basson, M. A., & Licht, J. D. (2006). Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. Trends in Cell Biology, 16(1), 45–54. doi: 10.1016/j.tcb.2005.11.004 . · DOI
  90. Mayer, C. E., Haigl, B., Jantscher, F., Siegwart, G., Grusch, M., Berger, W., et al. (2010). Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cellular and Molecular Life Sciences, 67(19), 3299–3311. doi: 10.1007/s00018-010-0379-6 . · DOI
  91. DaSilva, J., Xu, L., Kim, H. J., Miller, W. T., & Bar-Sagi, D. (2006). Regulation of sprouty stability by Mnk1-dependent phosphorylation. Molecular and Cellular Biology, 26(5), 1898–1907. doi: 10.1128/MCB.26.5.1898-1907.2006 . · DOI
  92. Edwin, F., Anderson, K., & Patel, T. B. (2010). HECT domain-containing E3 ubiquitin ligase Nedd4 interacts with and ubiquitinates Sprouty2. Journal of Biological Chemistry, 285(1), 255–264. doi: 10.1074/jbc.M109.030882 . · DOI
  93. Nadeau, R. J., Toher, J. L., Yang, X., Kovalenko, D., & Friesel, R. (2007). Regulation of Sprouty2 stability by mammalian Seven-in-Absentia homolog 2. Journal of Cellular Biochemistry, 100(1), 151–160. doi: 10.1002/jcb.21040 . · DOI
  94. Qi, J., Nakayama, K., Gaitonde, S., Goydos, J. S., Krajewski, S., Eroshkin, A., et al. (2008). The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proceedings of the National Academy of Sciences of the United States of America, 105(43), 16713–16718. doi: 10.1073/pnas.0804063105 . · DOI
  95. Haigl, B., Mayer, C. E., Siegwart, G., & Sutterluty, H. (2010). Sprouty4 levels are increased under hypoxic conditions by enhanced mRNA stability and transcription. Biological Chemistry, 391(7), 813–821. doi: 10.1515/bc.2010.082 . · DOI
  96. Anderson, K., Nordquist, K. A., Gao, X., Hicks, K. C., Zhai, B., Gygi, S. P., et al. (2011). Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins. [Research Support, N.I.H., Extramural]. Journal of Biological Chemistry, 286(49), 42027–42036. doi: 10.1074/jbc.M111.303222 . · DOI
  97. Lim, J., Wong, E. S., Ong, S. H., Yusoff, P., Low, B. C., & Guy, G. R. (2000). Sprouty proteins are targeted to membrane ruffles upon growth factor receptor tyrosine kinase activation. Identification of a novel translocation domain. Journal of Biological Chemistry, 275(42), 32837–32845. doi: 10.1074/jbc.M002156200 . · DOI
  98. Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002). Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. [Research Support, Non-U.S. Gov't]. Nature Cell Biology, 4(11), 850–858. doi: 10.1038/ncb867 . · DOI · Paper page
  99. Lim, J., Yusoff, P., Wong, E. S., Chandramouli, S., Lao, D. H., Fong, C. W., et al. (2002). The cysteine-rich sprouty translocation domain targets mitogen-activated protein kinase inhibitory proteins to phosphatidylinositol 4,5-bisphosphate in plasma membranes. Molecular and Cellular Biology, 22(22), 7953–7966. · DOI
  100. Cabrita, M. A., Jaggi, F., Widjaja, S. P., & Christofori, G. (2006). A functional interaction between sprouty proteins and caveolin-1. Journal of Biological Chemistry, 281(39), 29201–29212. doi: 10.1074/jbc.M603921200 . · DOI
  101. Hwangpo, T. A., Jordan, J. D., Premsrirut, P. K., Jayamaran, G., Licht, J. D., Iyengar, R., et al. (2012). G Protein-regulated inducer of neurite outgrowth (GRIN) modulates Sprouty protein repression of mitogen-activated protein kinase (MAPK) activation by growth factor stimulation. Journal of Biological Chemistry, 287(17), 13674–13685. doi: 10.1074/jbc.M111.320705 . · DOI
  102. Fong, C. W., Leong, H. F., Wong, E. S., Lim, J., Yusoff, P., & Guy, G. R. (2003). Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. [Research Support, Non-U.S. Gov't]. Journal of Biological Chemistry, 278(35), 33456–33464. doi: 10.1074/jbc.M301317200 . · DOI
  103. Rubin, C., Zwang, Y., Vaisman, N., Ron, D., & Yarden, Y. (2005). Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. Journal of Biological Chemistry, 280(10), 9735–9744. doi: 10.1074/jbc.M408308200 . · DOI
  104. Lao, D. H., Yusoff, P., Chandramouli, S., Philp, R. J., Fong, C. W., Jackson, R. A., et al. (2007). Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation. Journal of Biological Chemistry, 282(12), 9117–9126. doi: 10.1074/jbc.M607563200 . · DOI
  105. Lao, D. H., Chandramouli, S., Yusoff, P., Fong, C. W., Saw, T. Y., Tai, L. P., et al. (2006). A Src homology 3-binding sequence on the C terminus of Sprouty2 is necessary for inhibition of the Ras/ERK pathway downstream of fibroblast growth factor receptor stimulation. Journal of Biological Chemistry, 281(40), 29993–30000. doi: 10.1074/jbc.M604044200 . · DOI
  106. Chandramouli, S., Yu, C. Y., Yusoff, P., Lao, D. H., Leong, H. F., Mizuno, K., et al. (2008). Tesk1 interacts with Spry2 to abrogate its inhibition of ERK phosphorylation downstream of receptor tyrosine kinase signaling. Journal of Biological Chemistry, 283(3), 1679–1691. doi: 10.1074/jbc.M705457200 . · DOI
  107. Hanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K., & Nishida, E. (2004). Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. Journal of Biological Chemistry, 279(22), 22992–22995. doi: 10.1074/jbc.M312498200 . · DOI
  108. Jarvis, L. A., Toering, S. J., Simon, M. A., Krasnow, M. A., & Smith-Bolton, R. K. (2006). Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases. Development, 133(6), 1133–1142. doi: 10.1242/dev.02255 . · DOI
  109. Patel, R., Gao, M., Ahmad, I., Fleming, J., Singh, L. B., Rai, T. S., et al. (2013). Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Journal of Clinical Investigation, 123(3), 1157–1175. doi: 10.1172/jci63672 . · DOI
  110. Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G., & Bastiaens, P. I. (2002). Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science, 295(5560), 1708–1711. doi: 10.1126/science.1067566 . · DOI
  111. Egan, J. E., Hall, A. B., Yatsula, B. A., & Bar-Sagi, D. (2002). The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proceedings of the National Academy of Sciences of the United States of America, 99(9), 6041–6046. doi: 10.1073/pnas.052090899 . · DOI
  112. Wong, E. S., Lim, J., Low, B. C., Chen, Q., & Guy, G. R. (2001). Evidence for direct interaction between Sprouty and Cbl. Journal of Biological Chemistry, 276(8), 5866–5875. doi: 10.1074/jbc.M006945200 . · DOI
  113. Kim, H. J., Taylor, L. J., & Bar-Sagi, D. (2007). Spatial regulation of EGFR signaling by Sprouty2. Current Biology, 17(5), 455–461. doi: 10.1016/j.cub.2007.01.059 . · DOI
  114. Aranda, S., Alvarez, M., Turro, S., Laguna, A., & de la Luna, S. (2008). Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A. Molecular and Cellular Biology, 28(19), 5899–5911. doi: 10.1128/MCB.00394-08 . · DOI
  115. Reich, A., Sapir, A., & Shilo, B. (1999). Sprouty is a general inhibitor of receptor tyrosine kinase signaling. [Research Support, Non-U.S. Gov't]. Development, 126(18), 4139–4147. · DOI
  116. Tsavachidou, D., Coleman, M. L., Athanasiadis, G., Li, S. X., Licht, J. D., Olson, M. F., et al. (2004). SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Research, 64(16), 5556–5559. · DOI
  117. Yusoff, P., Lao, D. H., Ong, S. H., Wong, E. S., Lim, J., Lo, T. L., et al. (2002). Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. Journal of Biological Chemistry, 277(5), 3195–3201. doi: 10.1074/jbc.M108368200 . · DOI
  118. Ayada, T., Taniguchi, K., Okamoto, F., Kato, R., Komune, S., Takaesu, G., et al. (2009). Sprouty4 negatively regulates protein kinase C activation by inhibiting phosphatidylinositol 4,5-biphosphate hydrolysis. Oncogene, 28(8), 1076–1088. doi: 10.1038/onc.2008.464 . · DOI
  119. Taniguchi, K., Ishizaki, T., Ayada, T., Sugiyama, Y., Wakabayashi, Y., Sekiya, T., et al. (2009). Sprouty4 deficiency potentiates Ras-independent angiogenic signals and tumor growth. Cancer Science, 100(9), 1648–1654. doi: 10.1111/j.1349-7006.2009.01214.x . · DOI
  120. Haglund, K., Di Fiore, P. P., & Dikic, I. (2003). Distinct monoubiquitin signals in receptor endocytosis. Trends in Biochemical Sciences, 28(11), 598–603. doi: 10.1016/j.tibs.2003.09.005 . · DOI · Paper page
  121. Haglund, K., Sigismund, S., Polo, S., Szymkiewicz, I., Di Fiore, P. P., & Dikic, I. (2003). Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nature Cell Biology, 5(5), 461–466. doi: 10.1038/ncb983 . · DOI · Paper page
  122. Mosesson, Y., Shtiegman, K., Katz, M., Zwang, Y., Vereb, G., Szollosi, J., et al. (2003). Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. Journal of Biological Chemistry, 278(24), 21323–21326. doi: 10.1074/jbc.C300096200 . · DOI · Paper page
  123. Petrelli, A., Gilestro, G. F., Lanzardo, S., Comoglio, P. M., Migone, N., & Giordano, S. (2002). The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature, 416(6877), 187–190. doi: 10.1038/416187a . · DOI
  124. Soubeyran, P., Kowanetz, K., Szymkiewicz, I., Langdon, W. Y., & Dikic, I. (2002). Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature, 416(6877), 183–187. doi: 10.1038/416183a . · DOI
  125. Kowanetz, K., Szymkiewicz, I., Haglund, K., Kowanetz, M., Husnjak, K., Taylor, J. D., et al. (2003). Identification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors. Journal of Biological Chemistry, 278(41), 39735–39746. doi: 10.1074/jbc.M304541200 . · DOI
  126. Ng, C., Jackson, R. A., Buschdorf, J. P., Sun, Q., Guy, G. R., & Sivaraman, J. (2008). Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates. EMBO Journal, 27(5), 804–816. doi: 10.1038/emboj.2008.18 . · DOI
  127. Haglund, K., Schmidt, M. H., Wong, E. S., Guy, G. R., & Dikic, I. (2005). Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation. EMBO Reports, 6(7), 635–641. doi: 10.1038/sj.embor.7400453 . · DOI
  128. Ozaki, K., Miyazaki, S., Tanimura, S., & Kohno, M. (2005). Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. Journal of Cell Science, 118(Pt 24), 5861–5871. doi: 10.1242/jcs.02711 . · DOI
  129. Frolov, A., Chahwan, S., Ochs, M., Arnoletti, J. P., Pan, Z. Z., Favorova, O., et al. (2003). Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Molecular Cancer Therapeutics, 2(8), 699–709.
  130. Feng, Y. H., Tsao, C. J., Wu, C. L., Chang, J. G., Lu, P. J., Yeh, K. T., et al. (2010). Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Science, 101(9), 2033–2038. doi: 10.1111/j.1349-7006.2010.01637.x . · DOI
  131. Faratian, D., Sims, A. H., Mullen, P., Kay, C., Um, I., Langdon, S. P., et al. (2011). Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PLoS One, 6(8), e23772. doi: 10.1371/journal.pone.0023772 . · DOI
  132. Sirivatanauksorn, Y., Sirivatanauksorn, V., Srisawat, C., Khongmanee, A., & Tongkham, C. (2012). Differential expression of sprouty genes in hepatocellular carcinoma. Journal of Surgical Oncology, 105(3), 273–276. doi: 10.1002/jso.22095 . · DOI
  133. Song, K., Gao, Q., Zhou, J., Qiu, S. J., Huang, X. W., Wang, X. Y., et al. (2012). Prognostic significance and clinical relevance of Sprouty 2 protein expression in human hepatocellular carcinoma. [Research Support, Non-U.S. Gov't]. Hepatobiliary & Pancreatic Diseases International, 11(2), 177–184. · DOI
  134. McKie, A. B., Douglas, D. A., Olijslagers, S., Graham, J., Omar, M. M., Heer, R., et al. (2005). Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene, 24(13), 2166–2174. doi: 10.1038/sj.onc.1208371 . · DOI
  135. Winn, R. A., Marek, L., Han, S. Y., Rodriguez, K., Rodriguez, N., Hammond, M., et al. (2005). Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Journal of Biological Chemistry, 280(20), 19625–19634. doi: 10.1074/jbc.M409392200 . · DOI
  136. Feng, Y. H., Wu, C. L., Tsao, C. J., Chang, J. G., Lu, P. J., Yeh, K. T., et al. (2011). Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: Correlation with the clinical stage of the disease. Cancer Biology and Therapy, 11(1), 111–121. · DOI
  137. Dorman, K., Shen, Z., Yang, C., Ezzat, S., & Asa, S. L. (2012). CtBP1 interacts with Ikaros and modulates pituitary tumor cell survival and response to hypoxia. Molecular Endocrinology, 26(3), 447–457. doi: 10.1210/me.2011-1095 . · DOI
  138. Macia, A., Gallel, P., Vaquero, M., Gou-Fabregas, M., Santacana, M., Maliszewska, A., et al. (2012). Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma. Oncogene, 31(35), 3961–3972. doi: 10.1038/onc.2011.556 . · DOI
  139. Schutzman, J. L., & Martin, G. R. (2012). Sprouty genes function in suppression of prostate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 109(49), 20023–20028. doi: 10.1073/pnas.1217204109 . · DOI
  140. Lito, P., Mets, B. D., Kleff, S., O'Reilly, S., Maher, V. M., & McCormick, J. J. (2008). Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. Journal of Biological Chemistry, 283(4), 2002–2009. doi: 10.1074/jbc.M709046200 . · DOI
  141. Kanetsky, P. A., Mitra, N., Vardhanabhuti, S., Li, M., Vaughn, D. J., Letrero, R., et al. (2009). Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nature Genetics, 41(7), 811–815. doi: 10.1038/ng.393 . · DOI
  142. Kwabi-Addo, B., Wang, J., Erdem, H., Vaid, A., Castro, P., Ayala, G., et al. (2004). The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Research, 64(14), 4728–4735. doi: 10.1158/0008-5472.CAN-03-3759 . · DOI
  143. Minowada, G., & Miller, Y. E. (2009). Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis. American Journal of Respiratory Cell and Molecular Biology, 40(1), 31–37. doi: 10.1165/rcmb.2008-0147OC . · DOI · Paper page
  144. Mekkawy, A. H., De Bock, C. E., Lin, Z., Morris, D. L., Wang, Y., & Pourgholami, M. H. (2010). Novel protein interactors of urokinase-type plasminogen activator receptor. Biochemical and Biophysical Research Communications, 399(4), 738–743. doi: 10.1016/j.bbrc.2010.08.010 . · DOI
  145. Vanas, V., Muhlbacher, E., Kral, R., & Sutterluty-Fall, H. (2014). Sprouty4 interferes with cell proliferation and migration of breast cancer-derived cell lines. Tumour Biology. doi: 10.1007/s13277-013-1587-0 . · DOI
  146. Kwabi-Addo, B., Ren, C., & Ittmann, M. (2009). DNA methylation and aberrant expression of Sprouty1 in human prostate cancer. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Epigenetics, 4(1), 54–61. · DOI
  147. Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell, 18(1), 11–22. doi: 10.1016/j.ccr.2010.05.026 . · DOI
  148. Fritzsche, S., Kenzelmann, M., Hoffmann, M. J., Muller, M., Engers, R., Grone, H. J., et al. (2006). Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocrine-Related Cancer, 13(3), 839–849. doi: 10.1677/erc.1.01190 . · DOI
  149. Yap, T. A., Zivi, A., Omlin, A., & de Bono, J. S. (2011). The changing therapeutic landscape of castration-resistant prostate cancer. Nature Reviews. Clinical Oncology, 8(10), 597–610. doi: 10.1038/nrclinonc.2011.117 . · DOI
  150. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nature Genetics, 19(4), 348–355. doi: 10.1038/1235 . · DOI
  151. Chen, X., Cheung, S. T., So, S., Fan, S. T., Barry, C., Higgins, J., et al. (2002). Gene expression patterns in human liver cancers. Molecular Biology of the Cell, 13(6), 1929–1939. doi: 10.1091/mbc.02-02-0023 . · DOI
  152. Harada, N., Miyoshi, H., Murai, N., Oshima, H., Tamai, Y., Oshima, M., et al. (2002). Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Research, 62(7), 1971–1977.
  153. Harada, N., Oshima, H., Katoh, M., Tamai, Y., Oshima, M., & Taketo, M. M. (2004). Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Research, 64(1), 48–54. · DOI
  154. Lee, S. A., Ladu, S., Evert, M., Dombrowski, F., De Murtas, V., Chen, X., et al. (2010). Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology, 52(2), 506–517. doi: 10.1002/hep.23681 . · DOI
  155. Cho, H. C., Lai, C. Y., Shao, L. E., & Yu, J. (2011). Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma. Cancer Research, 71(23), 7250–7258. doi: 10.1158/0008-5472.can-11-0903 . · DOI
  156. Bren-Mattison, Y., Van Putten, V., Chan, D., Winn, R., Geraci, M. W., & Nemenoff, R. A. (2005). Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene, 24(8), 1412–1422. doi: 10.1038/sj.onc.1208333 . · DOI
  157. Winn, R. A., Van Scoyk, M., Hammond, M., Rodriguez, K., Crossno, J. T., Jr., Heasley, L. E., et al. (2006). Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry, 281(37), 26943–26950. doi: 10.1074/jbc.M604145200 . · DOI
  158. Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 6(1), 1–6. · DOI
  159. Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., et al. (2011). Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. European Journal of Cancer, 47(13), 1946–1954. doi: 10.1016/j.ejca.2011.03.029 . · DOI
  160. Huang, Z. P., Chen, J. F., Regan, J. N., Maguire, C. T., Tang, R. H., Dong, X. R., et al. (2010). Loss of microRNAs in neural crest leads to cardiovascular syndromes resembling human congenital heart defects. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(12), 2575–2586. doi: 10.1161/atvbaha.110.213306 . · DOI
  161. Bloethner, S., Chen, B., Hemminki, K., Muller-Berghaus, J., Ugurel, S., Schadendorf, D., et al. (2005). Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis, 26(7), 1224–1232. doi: 10.1093/carcin/bgi066 . · DOI
  162. Quigley, D. A., To, M. D., Kim, I. J., Lin, K. K., Albertson, D. G., Sjolund, J., et al. (2011). Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biology, 12(1), R5. doi: 10.1186/gb-2011-12-1-r5 . · DOI
  163. Mathieu, V., Pirker, C., Schmidt, W. M., Spiegl-Kreinecker, S., Lotsch, D., Heffeter, P., et al. (2012). Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget, 3(4), 399–413. · DOI
  164. Nielsen, T. O., West, R. B., Linn, S. C., Alter, O., Knowling, M. A., O'Connell, J. X., et al. (2002). Molecular characterisation of soft tissue tumours: a gene expression study. Lancet, 359(9314), 1301–1307. doi: 10.1016/s0140-6736(02)08270-3 . · DOI
  165. Rathmanner, N., Haigl, B., Vanas, V., Doriguzzi, A., Gsur, A., & Sutterluty-Fall, H. (2013). Sprouty2 but not Sprouty4 is a potent inhibitor of cell proliferation and migration of osteosarcoma cells. FEBS Letters, 587(16), 2597–2605. doi: 10.1016/j.febslet.2013.06.040 . · DOI
  166. Holtkamp, N., Mautner, V. F., Friedrich, R. E., Harder, A., Hartmann, C., Theallier-Janko, A., et al. (2004). Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathologica, 107(2), 159–168. doi: 10.1007/s00401-003-0797-8 . · DOI
  167. Sanchez, A., Setien, F., Martinez, N., Oliva, J. L., Herranz, M., Fraga, M. F., et al. (2008). Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas. Oncogene, 27(36), 4969–4972. doi: 10.1038/onc.2008.129 . · DOI
  168. Macia, A., Vaquero, M., Gou-Fabregas, M., Castelblanco, E., Valdivielso, J. M., Anerillas, C., et al. (2014). Sprouty1 induces a senescence-associated secretory phenotype by regulating NFkappaB activity: implications for tumorigenesis. Cell Death and Differentiation, 21(2), 333–343. doi: 10.1038/cdd.2013.161 . · DOI
  169. Polytarchou, C., Iliopoulos, D., Hatziapostolou, M., Kottakis, F., Maroulakou, I., Struhl, K., et al. (2011). Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Research, 71(13), 4720–4731. doi: 10.1158/0008-5472.can-11-0365 . · DOI
  170. Moghaddam, S. M., Amini, A., Wei, A. Q., Pourgholami, M. H., & Morris, D. L. (2012). Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. Journal of Oncology, 2012, 373826. doi: 10.1155/2012/373826 . · DOI
  171. Takahashi, M., Rhodes, D. R., Furge, K. A., Kanayama, H., Kagawa, S., Haab, B. B., et al. (2001). Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. [Comparative Study Research Support, Non-U.S. Gov't Validation Studies]. Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9754–9759. doi: 10.1073/pnas.171209998 . · DOI

Cited by

Sorted by citations

Metadata

Authors
Masoumi-Moghaddam, S., Amini, A., & Morris, D. L.
Venue
Cancer and Metastasis Reviews
Publisher
Springer Science and Business Media LLC
Published
2014-04-18
Volume
33
Issue
2-3
Pages
695-720
ISSN
  • 0167-7659
  • 1573-7233
DOI
10.1007/s10555-014-9497-1
PMC
PMC4113681
Cited by
150
References
5
Language
en
Licence
creativecommons.org/licenses/by/4.0 (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review